What is ENTX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.51B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ENTX?

P/E (TTM) is n/a and 52-week range is $0.91 to $4.20 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ENTX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ENTX?

The company profile lists revenue (TTM) near $225K, net income (TTM) near -$1.02B, EPS (TTM) near -$0.35 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Entera Bio Ltd based, and what identifiers does Chartloom list?

The company context section lists headquarters in Jerusalem, IL, 173.9M shares outstanding, ISIN IL0011429839 when available from company profile and filing metadata.

Entera Bio Ltd

$ENTX

Health Care · Biotechnology

IR Run Scenarios

Browse other companiesFree AI scores and summaries for more stocks

Entera Bio Ltd

$ENTX

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

Employees

20

Website

enterabio.com/

IPO

2018-06-28

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

IL0011429839

Headquarters

Jerusalem, IL

Shares outstanding

173.9M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

34.07%

Browse other companiesFree AI scores and summaries for more stocks

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

Employees

20

Website

enterabio.com/

IPO

2018-06-28

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)